3/27
01:22 pm
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) had its price target lowered by analysts at HC Wainwright from $21.00 to $13.00. They now have a "buy" rating on the stock.
Low
Report
PDS Biotechnology Co. (NASDAQ: PDSB) had its price target lowered by analysts at HC Wainwright from $21.00 to $13.00. They now have a "buy" rating on the stock.
3/27
07:30 am
pdsb
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update
Low
Report
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update
3/25
08:00 am
pdsb
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
Medium
Report
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
3/23
08:58 am
pdsb
PDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to Analysts [Yahoo! Finance]
Low
Report
PDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to Analysts [Yahoo! Finance]
3/18
08:00 am
pdsb
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results
Medium
Report
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results
3/13
01:58 pm
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Neutral
Report
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
3/13
08:06 am
pdsb
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer [Yahoo! Finance]
Medium
Report
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer [Yahoo! Finance]
3/13
08:00 am
pdsb
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
Low
Report
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
3/11
08:00 am
pdsb
PDS Biotech Leadership to Participate in March Conferences
Low
Report
PDS Biotech Leadership to Participate in March Conferences
3/7
12:54 pm
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Medium
Report
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
3/7
08:45 am
pdsb
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
Medium
Report
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
2/27
08:00 am
pdsb
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
High
Report
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2/26
08:00 am
pdsb
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology
Low
Report
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology
2/24
11:32 am
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Medium
Report
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
2/24
08:08 am
pdsb
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research [Yahoo! Finance]
High
Report
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research [Yahoo! Finance]
2/24
08:00 am
pdsb
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research
Medium
Report
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research
2/20
08:00 am
pdsb
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025
Medium
Report
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025
2/5
06:17 pm
pdsb
PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma [Yahoo! Finance]
Neutral
Report
PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma [Yahoo! Finance]
2/5
08:00 am
pdsb
PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Medium
Report
PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma